Andrew graduated from Nottingham in 2003 with a BMBS and entered clinical practice. He commenced the paediatric postgraduate training scheme in 2005. In 2009, he commenced a PhD in child health, and was awarded a NIHR Doctoral Research Fellowship in 2010, where he studied biomarkers of toxicity in children and adults with cystic fibrosis. After a further period of clinical practice he returned to research and holds a NIHR Academic Clinical Lecturer post in Child Health.
Clinical research studies: Andrew ran the CEFIT study (a cross sectional observational clinical study) and the CRITIC study (a randomised phase IV pharmacokinetic study). Andrew uses MWPharm for pharmaocokinetic modelling.
In the laboratory, Andrew measured biomarkers of kidney toxicity in urine samples.
Andrew has an interest in understanding how clinical trials influence research practice, and has ongoing projects in this area. Andrew is interested in applying machine learning to clinical problems.
Andrew teaches an informal seminar series on the R language for statistics within his division.
STEWART E, PRAYLE AP, TOOKE A, PASALODOS S, SURI M, BUSH A and BHATT JM, 2016. Growth and nutrition in children with ataxia telangiectasia. Archives of disease in childhood. 101(12), 1137-1141 HURLEY MN, , PRAYLE AP and FLUME P, 2015. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatric respiratory reviews. 16(4), 246-8 HURLEY MN, PRAYLE AP and FLUME P, 2015. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. The Cochrane database of systematic reviews. CD009730
PRAYLE AP, JAIN K, TOUW DJ, KOCH BC, KNOX AJ, WATSON A and SMYTH AR, 2015. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 15(4), 510-7